



Michael S Binkley, MD, MS

Assistant Professor of Radiation Oncology (Radiation Therapy)

Radiation Oncology - Radiation Therapy

CLINICAL OFFICE (PRIMARY)

- **Department of Radiation Oncology**

875 Blake Wilbur Dr

MC 5847

Stanford, CA 94305

Tel (650) 723-6171

Fax (650) 725-8231

Bio

BIO

Dr. Binkley is a radiation oncologist specializing in lymphoma treatment and an assistant professor in the Stanford University School of Medicine Department of Radiation Oncology.

His clinical expertise includes stereotactic ablative radiotherapy (SABR), total lymphoid and total body irradiation, and intensity modulated radiation therapy (IMRT).

For each patient, Dr. Binkley develops a personalized, comprehensive, and compassionate care plan. His goals are to improve both health and quality of life.

Dr. Binkley has conducted extensive research to advance cancer treatment. In his post-doctoral fellowship at Stanford, he studied the use of genomic signatures to predict response to radiotherapy. His current clinical and laboratory research seek to identify prognostic and predictive clinical, radiographic, and genomic factors to inform individualized treatment strategies.

He has co-authored articles on his research discoveries published in Cancer Discovery, Blood, the International Journal of Radiation Oncology*Biophysics, and elsewhere. Topics have included innovations in the treatment of lymphoma and lung cancer.

He also has made invited presentations to colleagues at national and international conferences. He has presented the latest findings on radiation therapy for lung cancer and lymphoma at meetings of the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and International Conference on Malignant Lymphoma (ICML).

Honors for Dr. Binkley include the Malcolm A. Bagshaw Award for leadership and outstanding scientific achievement. This award is named for a pioneer in radiation therapy and former chair of the Departments of Radiology and Radiation Oncology at Stanford University School of Medicine.

Dr. Binkley is a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, and American Association for Cancer Research. He is a founding member of the Global nLPHL One Working (GLOW) Working Group, an international collaboration studying nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in children and adults.

CLINICAL FOCUS

- Radiation Oncology
- Lymphoma

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Radiation Oncology - Radiation Therapy
- Member, Stanford Cancer Institute

PROFESSIONAL EDUCATION

- Board Certification: Radiation Oncology, American Board of Radiology (2022)
- Residency: Stanford University Radiation Oncology Residency (2021) CA
- Internship: Santa Clara Valley Medical Center Internal Medicine Residency (2017) CA
- Medical Education: Stanford University School of Medicine (2016) CA

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Shengqin Su

Publications

PUBLICATIONS

- **Investigating the tissue specificity and prognostic impact of cis-regulatory cancer risk variants.** *Human genetics*
Subramanian, A., Su, S., Moding, E. J., Binkley, M. S.
2023
- **Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG.** *Blood*
Binkley, M. S., Rauf, M. S., Milgrom, S. A., Pinnix, C. C., Tsang, R. W., Dickinson, M. n., Ng, A. n., Roberts, K. B., Gao, S. n., Balogh, A. G., Ricardi, U. n., Levis, M. n., Casulo, et al
2020
- **KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.** *Cancer discovery*
Binkley, M. S., Jeon, Y. J., Nesselbush, M. n., Moding, E. J., Nabet, B. Y., Almanza, D. n., Kunder, C. n., Stehr, H. n., Yoo, C. H., Rhee, S. n., Xiang, M. n., Chabon, J. J., Hamilton, et al
2020
- **Salvage treatment and survival for relapsed follicular lymphoma following primary radiotherapy: A collaborative study on behalf of ILROG.** *International journal of radiation oncology, biology, physics*
Binkley, M. S., Brady, J. L., Hajj, C., Chelius, M., Chau, K., Balogh, A., Levis, M., Filippi, A. R., Jones, M., Ahmed, S., MacManus, M., Wirth, A., Oguchi, et al
2019
- **Definitive radiotherapy for localized follicular lymphoma staged by F-18-FDG PET-CT: a collaborative study by ILROG BLOOD**
Brady, J. L., Binkley, M. S., Hajj, C., Chelius, M., Chau, K., Balogh, A., Levis, M., Filippi, A., Jones, M., Mac Manus, M., Wirth, A., Oguchi, M., Vistisen, et al
2019; 133 (3): 237–45
- **Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.** *EJHaem*
Lee, D., Goyal, A., Wang, W. L., Ananth, S., Lau, E., Binkley, M. S., Bharadwaj, S., Dahiya, S.

2024; 5 (1): 153-156

- **Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.** *Nature*
Alig, S. K., Esfahani, M. S., Garofalo, A., Li, M. Y., Rossi, C., Flerlage, T., Flerlage, J. E., Adams, R., Binkley, M. S., Shukla, N., Jin, M. C., Olsen, M., Telenius, et al
2023
- **Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer.** *JACC. CardioOncology*
No, H. J., Guo, F. B., Park, N. J., Kastelowitz, N., Rhee, J. W., Clark, D. E., Chin, A. L., Vitzthum, L. K., Horst, K. C., Moding, E. J., Loo, B. W., Diehn, M., Binkley, et al
2023; 5 (6): 775-787
- **Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods**
Alig, S. K., Esfahani, M., Garofalo, A., Li, M., Rossi, C., Flerlage, T., Flerlage, J. E., Adams, R., Binkley, M. S., Shukla, N., Jin, M., Olsen, M., Telenius, et al
AMER SOC HEMATOLOGY.2023
- **Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification**
Mutter, J. A., Esfahani, M., Schroers-Martin, J., Alig, S. K., Hamilton, M. P., Sworder, B. J., Tessoulin, B., Boegeholz, J., Flerlage, T., Flerlage, J. E., Binkley, M. S., Sugio, T., Rossi, et al
AMER SOC HEMATOLOGY.2023
- **Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)**
Bharadwaj, S., Lau, E., Hashmi, A., Hamilton, M. P., Jensen, A., Goyal, A., Marar, M., Lee, C., Ananth, S., Sahaf, B., Mallampet, J., Ehlinger, Z., Syal, et al
AMER SOC HEMATOLOGY.2023
- **The pathobiology of select adolescent young adult lymphomas.** *EJHaem*
Steidl, C., Kridel, R., Binkley, M., Morton, L. M., Chadburn, A.
2023; 4 (4): 892-901
- **Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.** *Clinical lymphoma, myeloma & leukemia*
Binkley, M. S., Advani, R. H.
2023
- **Spatial phenotyping of Nodular Lymphocyte Predominant Hodgkin Lymphoma and T-cell/Histiocyte-Rich Large B-cell Lymphoma using PhenoCycler (formerly CODEX)**
Younes, S., Subramanian, A., Khan, A., Zhao, S., Binkley, M., Natkunam, Y.
ELSEVIER SCIENCE INC.2023: S1261-S1262
- **Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.** *Blood*
Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., Frank, M. J., Johnston, L. J., Miklos, D. B., Muffly, L., Negrin, R. S., Rezvani, A. R., Shiraz, et al
2023
- **Investigating and modeling positron emission tomography factors associated with large cell transformation from low-grade lymphomas.** *EJHaem*
Obeid, J. P., Hiniker, S. M., Schroers-Martin, J., Guo, H. H., No, H. J., Moding, E. J., Advani, R. H., Alizadeh, A. A., Hoppe, R. T., Binkley, M. S.
2023; 4 (1): 90-99
- **STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer.** *JCO precision oncology*
Katipally, R. R., Spurr, L. F., Gutiontov, S. I., Turchan, W. T., Connell, P., Juloori, A., Malik, R., Binkley, M. S., Jiang, A. L., Rouhani, S. J., Chervin, C. S., Wanjari, P., Segal, et al
2023; 7: e2200273
- **Investigating Metabolic Response after CAR-T Therapy and Bridging Radiotherapy for Relapsed/Refractory B-Cell Lymphoma**
Marar, M., Hiniker, S., Hoppe, R., Binkley, M.
AMER SOC HEMATOLOGY.2022: 12786-12787
- **Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma.** *Cureus*
Hui, C., Wu, Y. F., Liu, K., Sandhu, N., Blomain, E., Binkley, M. S., Gephart, M. H., Chang, S. D., Li, G. H., Reddy, S. A., Soltys, S. G., Pollom, E.
2022; 14 (11): e31838

- **Analysis of Metabolic Tumor Volume in Patients Undergoing Radiotherapy Prior to or After CAR-T Therapy for Relapsed/refractory Aggressive B Cell Lymphoma**
Marar, M., Hiniker, S., Hoppe, R., Binkley, M.
LIPPINCOTT WILLIAMS & WILKINS.2022: S12-S13
- **Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma.** *British journal of haematology*
Binkley, M. S.
2022
- **The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer.** *Cancer research communications*
Sodji, Q. H., Nambiar, D. K., Viswanathan, V., von Eyben, R., Colburg, D., Binkley, M. S., Li, C. G., Olcina, M. M., Chang, D. T., Le, Q., Giaccia, A. J.
2022; 2 (7): 725-738
- **Inferring gene expression from cell-free DNA fragmentation profiles.** *Nature biotechnology*
Esfahani, M. S., Hamilton, E. G., Mehrmohamadi, M., Nabet, B. Y., Alig, S. K., King, D. A., Steen, C. B., Macaulay, C. W., Schultz, A., Nesselbush, M. C., Soo, J., Schroers-Martin, J. G., Chen, et al
2022
- **Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW).** *Leukemia & lymphoma*
Lo, A. C., Major, A., Super, L., Appel, B., Shankar, A., Constine, L. S., Marks, L. J., Kelly, K. M., Metzger, M. L., Buhtoiarov, I. N., Mauz-Korholz, C., Costa, A. R., Binkley, et al
2022: 1-4
- **Radiotherapy for brain metastases from thyroid cancer: an institutional and national retrospective cohort study.** *Thyroid : official journal of the American Thyroid Association*
Blomain, E. S., Berta, S., Hug, N. F., Giao, D. M., Meola, A., Binkley, M. S., Hui, C., Churilla, T., Shahsavari, N., Desai, K., Chang, S. D., Soltys, S., Pollom, et al
2022
- **Digital Spatial Profiling Reveals Spatial Heterogeneity in Nodular Lymphocyte-Predominant Hodgkin Lymphoma**
Rojansky, R., Younes, S., Subramanian, A., Binkley, M., Natkunam, Y.
SPRINGERNATURE.2022: 1008-1009
- **Digital Spatial Profiling Reveals Spatial Heterogeneity in Nodular Lymphocyte-Predominant Hodgkin Lymphoma**
Rojansky, R., Younes, S., Subramanian, A., Binkley, M., Natkunam, Y.
SPRINGERNATURE.2022: 1008-1009
- **Acute and Late Esophageal Toxicity Following Stereotactic Ablative Radiotherapy to Thoracic Tumors near or Abutting the Esophagus.** *International journal of radiation oncology, biology, physics*
Sodji, Q. H., Ko, R., von Eyben, R., Owen, S. G., Capaldi, D. P., Bush, K., Binkley, M. S., Alrowais, F., Pickthorn, B., Maxim, P. G., Gensheimer, M. F., Diehn, M., Loo, et al
1800
- **RADIO THERAPY FOR BRAIN METASTASES FROM THYROID CANCER: A RETROSPECTIVE COHORT STUDY**
Blomain, E., Berta, S., Hug, N., Giao, D., Meola, A., Binkley, M., Shahsavari, N., Desai, K., Chang, S., Soltys, S., Pollom, E.
OXFORD UNIV PRESS INC.2021: 42
- **Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma**
Hui, C., Wu, Y., Liu, K., Sandhu, N., Blomain, E., Binkley, M., Gephart, M., Chang, S., Li, G., Reddy, S., Gibbs, I., Soltys, S., Pollom, et al
LIPPINCOTT WILLIAMS & WILKINS.2021: S48-S49
- **Radiotherapy for Management of Brain Metastases from Thyroid Cancer: A National Cancer Database Study**
Blomain, E., Binkley, M., Giao, D., Churilla, T., Soltys, S., Pollom, E.
LIPPINCOTT WILLIAMS & WILKINS.2021: S48
- **Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., Yoo, C., Kurtz, D. M., Owen, S., Backhus, L. M., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER ASSOC CANCER RESEARCH.2021

- **Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy.** *Leukemia & lymphoma*
Binkley, M. S., Hiniker, S. M., Younes, S., Yoo, C., Wignarajah, A., Jin, M., Guo, H. H., Gupta, N. K., Natkunam, Y., Advani, R. H., Hoppe, R. T.
2021: 1–15
- **Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma.** *Blood*
Haebe, S. E., Shree, T. n., Sathe, A. n., Day, G. n., Czerwinski, D. K., Grimes, S. n., Lee, H. n., Binkley, M. S., Long, S. R., Martin, B. A., Ji, H. P., Levy, R. n.
2021
- **KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., Yoo, C., Kurtz, D., Owen, S., Backhus, L., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume.** *Radiation oncology (London, England)*
Binkley, M. S., Koenig, J. L., Kashyap, M. n., Xiang, M. n., Liu, Y. n., Sodji, Q. n., Maxim, P. G., Diehn, M. n., Loo, B. W., Gensheimer, M. F.
2020; 15 (1): 114
- **Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Binkley, M. S., Brady, J. L., Hajj, C., Chelius, M., Chau, K., Balogh, A., Levis, M., Filippi, A., Jones, M., Ahmed, S., MacManus, M., Wirth, A., Oguchi, et al
2019; 104 (3): 522–29
- **Detection of Solid Tumor Molecular Residual Disease(MRD) Using Circulating Tumor DNA (ctDNA)** *MOLECULAR DIAGNOSIS & THERAPY*
Chin, R., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., Chaudhuri, A. A.
2019; 23 (3): 311–31
- **Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).** *Molecular diagnosis & therapy*
Chin, R. I., Chen, K. n., Usmani, A. n., Chua, C. n., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., Chaudhuri, A. A.
2019
- **Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG.** *Blood*
Brady, J. L., Binkley, M. S., Hajj, C., Chelius, M., Chau, K., Balogh, A., Levis, M., Filippi, A. R., Jones, M., Mac Manus, M., Wirth, A., Oguchi, M., Krog Vistisen, et al
2018
- **F-18-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Qian, Y., Von Eyben, R., Liu, Y., Chin, F. T., Miao, Z., Apte, S., Carter, J. N., Binkley, M. S., Pollom, E. L., Harris, J. P., Prionas, N. D., Kissel, M., Simmons, et al
2018; 102 (4): 1183–92
- **18F-EF5 Pet-Based Imageable Hypoxia Predicts for Local Control in Tumors Treated With Conformal Radiotherapy**
Qian, Y., Liu, Y., Von Eyben, R., Carter, J. N., Pollom, E. L., Harris, J. P., Prionas, N. D., Binkley, M. S., Simmons, A., Diehn, M., Chin, F. T., Shultz, D. B., Brown, et al
ELSEVIER SCIENCE INC.2018: E17–E18
- **18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy.** *International journal of radiation oncology, biology, physics*
Qian, Y. n., Von Eyben, R. n., Liu, Y. n., Chin, F. T., Miao, Z. n., Apte, S. n., Carter, J. N., Binkley, M. S., Pollom, E. L., Harris, J. P., Prionas, N. D., Kissel, M. n., Simmons, et al
2018
- **Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging**
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Zhou, L., Liu, C., Scherer, F., Kurtz, D. M., Esfahani, M. S., Say, C., Carter, et al
ELSEVIER SCIENCE INC.2017: E4
- **Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung.** *Radiotherapy and oncology*
Binkley, M. S., King, M. T., Shrager, J. B., Bush, K., Chaudhuri, A. A., Popat, R., Gensheimer, M. F., Maxim, P. G., Henry Guo, H., Diehn, M., Nair, V. S., Loo, B. W.
2017; 123 (2): 270-275

- **Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.** *Cancer discovery*
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H. n., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L. n., Scherer, F. n., Kurtz, D. M., Say, et al
2017
- **Partial orbit irradiation achieves excellent outcomes for primary orbital lymphoma.** *Practical radiation oncology*
Binkley, M. S., Hiniker, S. M., Donaldson, S. S., Hoppe, R. T.
2016; 6 (4): 255-261
- **Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).** *Radiotherapy and oncology*
Chaudhuri, A. A., Binkley, M. S., Rigdon, J., Carter, J. N., Aggarwal, S., Dudley, S. A., Qian, Y., Kumar, K. A., Hara, W. Y., Gensheimer, M., Nair, V. S., Maxim, P. G., Shultz, et al
2016; 119 (3): 454-460
- **Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery** *SEMINARS IN RADIATION ONCOLOGY*
Hiniker, S. M., Modlin, L. A., Choi, C. Y., Atalar, B., Seiger, K., Binkley, M. S., Harris, J. P., Liao, Y. J., Fischbein, N., Wang, L., Ho, A., Lo, A., Chang, et al
2016; 26 (2): 97-104
- **Tracheal Diverticulum Following Paratracheal Hypofractionated Radiotherapy in the Setting of Prior and Subsequent Bevacizumab** *CUREUS*
Chaudhuri, A. A., Chen, J., Carter, J. N., Binkley, M. S., Kumar, K. A., Dudley, S. A., Sung, A. W., Loo, B. W.
2016; 8 (4)
- **Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery.** *Seminars in radiation oncology*
Hiniker, S. M., Modlin, L. A., Choi, C. Y., Atalar, B., Seiger, K., Binkley, M. S., Harris, J. P., Liao, Y. J., Fischbein, N., Wang, L., Ho, A., Lo, A., Chang, et al
2016; 26 (2): 97-104
- **Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation.** *International journal of radiation oncology, biology, physics*
Binkley, M. S., Hiniker, S. M., Chaudhuri, A., Maxim, P. G., Diehn, M., Loo, B. W., Shultz, D. B.
2016; 94 (4): 808-815
- **Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors** *RADIATION ONCOLOGY*
Binkley, M. S., Shrager, J. B., Chaudhuri, A., Popat, R., Maxim, P. G., Shultz, D. B., Diehn, M., Loo, B. W.
2016; 11
- **A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy** *LEUKEMIA & LYMPHOMA*
Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mitra, E. S., Advani, R. H., Hoppe, R. T.
2016; 57 (3): 604-608
- **A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.** *Leukemia & lymphoma*
Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mitra, E. S., Advani, R. H., Hoppe, R. T.
2016; 57 (3): 604-608
- **Severe Chest Wall Toxicity From Cryoablation in the Setting of Prior Stereotactic Ablative Radiotherapy** *CUREUS*
Chaudhuri, A. A., Binkley, M. S., Aggarwal, S., Qian, Y., Carter, J. N., Shah, R., Loo, B. W.
2016; 8 (2)
- **Severe Chest Wall Toxicity From Cryoablation in the Setting of Prior Stereotactic Ablative Radiotherapy.** *Cure^{us}*
Chaudhuri, A. A., Binkley, M. S., Aggarwal, S., Qian, Y., Carter, J. N., Shah, R., Loo, B. W.
2016; 8 (2)
- **Tracheal Diverticulum Following Paratracheal Hypofractionated Radiotherapy in the Setting of Prior and Subsequent Bevacizumab.** *Cure^{us}*
Chaudhuri, A. A., Chen, J. J., Carter, J. N., Binkley, M. S., Kumar, K. A., Dudley, S. A., Sung, A. W., Loo, B. W.
2016; 8 (4)
- **Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors.** *Radiation oncology*

Binkley, M. S., Shrager, J. B., Chaudhuri, A., Popat, R., Maxim, P. G., Shultz, D. B., Diehn, M., Loo, B. W.
2016; 11 (1): 40-?

- **Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.** *Seminars in radiation oncology*
Chaudhuri, A. A., Binkley, M. S., Osmundson, E. C., Alizadeh, A. A., Diehn, M.
2015; 25 (4): 305-312
- **Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Binkley, M. S., Trakul, N., Jacobs, L. R., von Eyben, R., Quynh-Thu Le, Q. T., Maxim, P. G., Loo, B. W., Shultz, D. B., Diehn, M.
2015; 92 (5): 1044-1052
- **Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors** *LUNG CANCER*
Chaudhuri, A. A., Tang, C., Binkley, M. S., Jin, M., Wynne, J. F., von Eyben, R., Hara, W. Y., Trakul, N., Loo, B. W., Diehn, M.
2015; 89 (1): 50-56
- **Lung Volume Reduction After Stereotactic Ablative Radiation Therapy of Lung Tumors: Potential Application to Emphysema** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Binkley, M. S., Shrager, J. B., Leung, A. N., Popat, R., Trakul, N., Atwood, T. F., Chaudhuri, A., Maxim, P. G., Diehn, M., Loo, B. W.
2014; 90 (1): 216-223
- **Lung volume reduction after stereotactic ablative radiation therapy of lung tumors: potential application to emphysema.** *International journal of radiation oncology, biology, physics*
Binkley, M. S., Shrager, J. B., Leung, A. N., Popat, R., Trakul, N., Atwood, T. F., Chaudhuri, A., Maxim, P. G., Diehn, M., Loo, B. W.
2014; 90 (1): 216-223